Inventagelab
Public Β· 3 known investors
Inventage Lab develops microfluidic-based drug-delivery platform technologies for long-acting injectables, high-concentration biologics, and gene and nucleic-acid therapeutics, offering control over particle uniformity and release kinetics along with scale-up to GMP manufacturing. It serves biopharmaceutical partners across the drug formulation and delivery cycle, from R&D through commercial production.
Also known as Inventage Lab Β· Inventage Lab, Inc. Β· InventageLab Β· μΈλ²€ν°μ§λ©
Founders & leadership
Investors Β· 3
Company profile
researched Aug 2026Inventage Lab, Inc. is a Seongnam, South Korea-based pharmaceutical company built around microfluidic drug delivery system (DDS) technology. Its platforms are used to develop and mass-produce long-acting injectables and genetic-material delivery formulations, with the company describing capabilities spanning particle uniformity, tunable release kinetics and scale-up from R&D to commercial manufacturing.
The company markets three named platforms: IVL-DrugFluidic, a long-acting injectable (LAI) platform producing uniform microspheres for tunable release; IVL-BioFluidic, an ultra-concentrated biologics platform aimed at stable, low-viscosity subcutaneous formulations; and IVL-GeneFluidic, a nucleic-acid delivery platform for controlled lipid nanoparticle (LNP) manufacturing. These sit on top of Laminar-FLUIDigm, its proprietary microfluidic engine that uses laminar flow control to produce ultra-uniform microspheres with batch-to-batch reproducibility.
Beyond platform technology, Inventage Lab researches, manufactures and sells human medicines addressing male pattern baldness, dementia and prostate cancer, among others, and also operates in veterinary medicines including combination drugs and chemical castration agents. Named pipeline assets include IVL3001 for male pattern hair loss and IVL3004 for drug addiction, alongside long-acting and oral formulation work on obesity and diabetes compounds such as semaglutide, tirzepatide and orforglipron.
Business model
The company develops and mass-produces micro/nano drug delivery systems using microfluidics, commercializing sustained-release injectables based on polymeric microspheres and manufacturing lipid nano delivery systems such as liposomes and LNPs. It also researches, manufactures and sells human and veterinary medicines.
Traction
The company reports completed microfluidics-based production infrastructure and an IND filing for a global Phase 2 trial of IVL3001 for male pattern hair loss (December 2025), selection for the Global TIPS program to advance late-stage global clinical development of the drug-addiction therapy IVL3004 (August 2026), patent registrations for an oral semaglutide formulation and a long-acting orforglipron injectable, and a disclosed KRW 98.5 billion financing with participation from bio-focused venture capital investors (March 2026).
Latest developments
Announcements through 2026 include the KRW 98.5 billion capital raise disclosed in March 2026, patent registrations for orforglipron long-acting injectable (January 2026) and oral semaglutide formulation (May 2026), clinical data presentations for CNS long-acting injectables (April 2026), obesity and diabetes LAI research at the American Diabetes Association meeting (May-June 2026), participation in BIO US 2026 (June 2026), presentation of mRNA-LNP mass-production platform results at CRS 2026 (July 2026), and final selection for the Global TIPS program supporting late-stage global trials of IVL3004 (August 2026).
βΈFull profile β market position, technology, go-to-market, geography, history
Market position
A publicly listed Korean pharmaceutical company classified under Other Pharmaceuticals, with roughly 73 employees and a market capitalization of approximately $280 million as quoted in August 2026. Quratis Inc. holds 40.87% of the company, and CEO Ju-Hee Kim holds 10.94%.
Technology
Laminar-FLUIDigm is the core proprietary microfluidic system, using stable laminar flow control to produce ultra-uniform microspheres with precise release kinetics, batch-to-batch reproducibility and scalability from R&D to commercial manufacturing. Three platforms build on it: IVL-DrugFluidic for long-acting injectable microspheres, IVL-BioFluidic for stable low-viscosity ultra-concentrated biologics suited to subcutaneous injection, and IVL-GeneFluidic for controlled, uniform and scalable LNP manufacturing for nucleic-acid delivery. The company has also reported mRNA-LNP mass-production platform results and holds formulation patents covering oral semaglutide and long-acting orforglipron.
Go-to-market
The company pursues partnering and business development, presenting technical results at scientific conferences including the Controlled Release Society meeting, the American Diabetes Association meeting and a neuroscience congress, and attending BIO US to expand global partnerships and technology collaboration.
Biopharmaceutical partners and pharmaceutical developers seeking formulation, drug delivery and manufacturing platforms; end markets include human therapeutics (hair loss, dementia, prostate cancer, obesity and diabetes, drug addiction, CNS indications) and veterinary medicines.
Geography
Headquartered in Seongnam-si, Gyeonggi-do, South Korea, with offices listed at 12 Yanghyeong-ro 405 beon-gil and at 24 Duncheon-daero, Seongnam-si. Activities extend internationally through global clinical development, US conference participation and global partnering efforts.
History
Founded in 2015, with CEO Ju-Hee Kim serving since May 2015. The company became publicly traded in Korea (ticker A389470). In March 2026 it announced funding of KRW 89.99724455 billion from a group of investors and separately provided KRW 10.000000167 billion in funding to Quratis Inc.
Compiled by commissioned research from 7 cited public sources β announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed β not independently audited.
Timeline Β· 11
launches, deals, and filingsCompany press release announcing a KRW 98.5 billion capital raise with broad participation from biotech-specialist VCs; a related exchange disclosure dated March 15 reports KRW 89.99724455 billion received from a group of investors.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
βΈResearch sources Β· 7
primary sources listed
- Inventagelabinventagelab.com Β· web
7 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Inventagelab do?
- Korean pharmaceutical company developing microfluidic drug-delivery platforms for long-acting injectables, biologics and nucleic acids.
- Who are Inventagelab's investors?
- Inventagelab's investors include Aju IB Invesment Corporation, Kiwoom Investment, We Ventures.